ALT Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -456900% compared to Altimmune's net margin of -49.65%. Altimmune's return on equity of -64.43% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Altimmune has a consensus price target of $22.86, signalling upside risk potential of 194.55%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 620.92%. Given that NovaBay Pharmaceuticals has higher upside potential than Altimmune, analysts believe NovaBay Pharmaceuticals is more attractive than Altimmune.

Altimmune has a beta of 0.155, which suggesting that the stock is 84.488% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Altimmune's net income of -$22.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Altimmune's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 10,121.98x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -456900% compared to Altimmune's net margin of --. Altimmune's return on equity of -64.43% beat Oragenics's return on equity of --.

Altimmune has a consensus price target of $22.86, signalling upside risk potential of 194.55%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 24523.8%. Given that Oragenics has higher upside potential than Altimmune, analysts believe Oragenics is more attractive than Altimmune.

Altimmune has a beta of 0.155, which suggesting that the stock is 84.488% less volatile than S&P 500. In comparison Oragenics has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.551%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are larger than Oragenics quarterly revenues of --. Altimmune's net income of -$22.8M is lower than Oragenics's net income of -$2.5M. Notably, Altimmune's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 10,121.98x versus 1.44x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -456900% compared to Altimmune's net margin of -2357.27%. Altimmune's return on equity of -64.43% beat Palatin Technologies's return on equity of --.

Altimmune has a consensus price target of $22.86, signalling upside risk potential of 194.55%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1652.58%. Given that Palatin Technologies has higher upside potential than Altimmune, analysts believe Palatin Technologies is more attractive than Altimmune.

Altimmune has a beta of 0.155, which suggesting that the stock is 84.488% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are smaller than Palatin Technologies quarterly revenues of $350K. Altimmune's net income of -$22.8M is lower than Palatin Technologies's net income of -$7.8M. Notably, Altimmune's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 10,121.98x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -456900% compared to Altimmune's net margin of --. Altimmune's return on equity of -64.43% beat Theriva Biologics's return on equity of --.

Altimmune has a consensus price target of $22.86, signalling upside risk potential of 194.55%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 6861.54%. Given that Theriva Biologics has higher upside potential than Altimmune, analysts believe Theriva Biologics is more attractive than Altimmune.

Altimmune has a beta of 0.155, which suggesting that the stock is 84.488% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

Altimmune has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Altimmune quarterly revenues are $5K, which are larger than Theriva Biologics quarterly revenues of --. Altimmune's net income of -$22.8M is lower than Theriva Biologics's net income of -$7.7M. Notably, Altimmune's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune is 10,121.98x versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.